Dr. Anderson on the GRIFFIN Study With D-RVd in Multiple Myeloma

Partner | Cancer Centers | <b>UT Soutwestern</b>

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Larry Anderson, MD, PhD, associate professor, Department of Internal Medicine, Division of Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

One of the key studies that was presented at 2019 ASH Annual Meeting is the GRIFFIN study, says Anderson. That randomized trial evaluated the use of up-front daratumumab with RVd. The stringent complete response (sCR) rate after a median follow-up of 22.1 months was 62.6% with D-RVd versus 45.4% with RVd (odds ratio, 1.98; 95% CI, 1.12-3.49; P = .0177). The overall CR rate was also improved with D-RVd, at 79.8% versus 60.8% (P = .0045), and the proportion of patients achieving minimal residual disease negativity was twice as high with D-RVd. At 24 months, both regimens had led to progression-free survival rates exceeding 85% and overall survival rates exceeding 90%. In that study physicians are seeing significantly more deep remissions and molecular remissions, or minimal residual disease negativity, concludes Anderson.